1. Home
  2. MDWD vs AMRN Comparison

MDWD vs AMRN Comparison

Compare MDWD & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MediWound Ltd.

MDWD

MediWound Ltd.

HOLD

Current Price

$18.79

Market Cap

238.5M

Sector

Health Care

ML Signal

HOLD

Logo Amarin Corporation plc

AMRN

Amarin Corporation plc

HOLD

Current Price

$14.14

Market Cap

339.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MDWD
AMRN
Founded
2000
1989
Country
Israel
Ireland
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
238.5M
339.8M
IPO Year
2014
1993

Fundamental Metrics

Financial Performance
Metric
MDWD
AMRN
Price
$18.79
$14.14
Analyst Decision
Strong Buy
Strong Sell
Analyst Count
2
1
Target Price
$37.50
$12.00
AVG Volume (30 Days)
84.8K
87.2K
Earning Date
11-20-2025
10-29-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$20,932,000.00
$226,733,000.00
Revenue This Year
$15.89
N/A
Revenue Next Year
$25.33
N/A
P/E Ratio
N/A
N/A
Revenue Growth
6.15
N/A
52 Week Low
$14.14
$7.08
52 Week High
$22.51
$20.90

Technical Indicators

Market Signals
Indicator
MDWD
AMRN
Relative Strength Index (RSI) 54.69 41.21
Support Level $18.55 $13.50
Resistance Level $18.96 $14.30
Average True Range (ATR) 0.57 0.75
MACD 0.01 -0.00
Stochastic Oscillator 55.79 25.43

Price Performance

Historical Comparison
MDWD
AMRN

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

About AMRN Amarin Corporation plc

Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.

Share on Social Networks: